The Medicare Part D redesign is expected to be a net financial negative for AbbVie, Johnson & Johnson and Merck in 2025 because a new price discount mainly targeting high-cost specialty drugs will outstrip any revenue boost driven by the improved adherence from a first-ever cap on beneficiary cost-sharing obligations.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?